Scholar Rock shares jump 300% after rare disease drug scores trial …

Oct 7, 2024 · A rival drug from Biohaven , opens new tab, also focusing on muscle retention, is in late-stage development for the disease. Scholar Rock expects to file for FDA approval in the …

CouponFollow Extension

300%
OFF

Scholar Rock Shares Jump 300% After Rare Disease Drug Scores Trial …

3 weeks from now

Oct 7, 2024 · A rival drug from Biohaven , opens new tab, also focusing on muscle retention, is in late-stage development for the disease. Scholar Rock expects to file for FDA approval in the …

reuters.com

315%
OFF

Scholar Rock's Stock Soars More Than 315% On Positive Trial Of ...

3 weeks from now

Oct 7, 2024 · Scholar Rock Holding Corp.'s stock soared more than 315% Monday to put it on track for its biggest ever one-day gain, after the clinical-stage biotech company said a late …

morningstar.com

30%
OFF

Scholar Rock Preps Filings After SMA Antibody Clears Trial

3 weeks from now

Oct 8, 2024 · Scholar Rock market cap hits $2.7bn after spinal muscular atrophy drug ... SMA is a genetic disorder that can cause rapid and ... was 30% with Scholar Rock's drug compared to …

pharmaphorum.com

300%
OFF

Scholar Rock’s Shares Soar 300% After Phase III Win In ... - BioSpace

3 weeks from now

Oct 8, 2024 · Scholar Rock on Monday announced that its investigational myostatin blocker apitegromab aced the Phase III SAPPHIRE trial in spinal muscular atrophy, demonstrating …

biospace.com

8%
OFF

SRRK Stock Soars As Muscle Disease Drug Meets Phase III Study Goal

3 weeks from now

Oct 8, 2024 · Interestingly, following the positive data readout from Scholar Rock’s late-stage SMA study, Biohaven BHVN also gained 10.8% on Monday. This is likely because the …

nasdaq.com

50%
OFF

Scholar Rock Shares Quadruple On Positive Drug-Study Results

3 weeks from now

Oct 7, 2024 · Shares of Scholar Rock rose to $31.36 in mid-day trading, up from $7.42 on Friday, though shares are still off more than 50% from their intraday peak of $68.02 in March 2021, …

wsj.com

$24.24
OFF

Scholar Rock Surges As Genetic Disease Drug Succeeds In Late-stage ...

3 weeks from now

Oct 7, 2024 · ** Shares of Scholar Rock NASDAQ:SRRK more than triple in value to $24.24 premarket ** Says its drug, apitegromab, met the main goal in a late-stage trial in patients with …

tradingview.com

$300
OFF

Scholar Rock Scores $300M For Regulatory Filings & Launch Plans …

3 weeks from now

Oct 9, 2024 · Late Tuesday, Scholar Rock priced an offering of more than 10.2 million shares at $28.25 each. The offering includes pre-funded warrants to purchase 353,983 shares at the …

medcitynews.com

$31.91
OFF

Scholar Rock Surges As Genetic Disease Drug Succeeds In Late-stage ...

3 weeks from now

Oct 7, 2024 · ** Shares of Scholar Rock NASDAQ:SRRK more than quadruple in value to $31.91** Stock set to hit nearly 3-year high if gains hold ** Says its drug, apitegromab, met the …

tradingview.com

300%
OFF

Scholar Rock Shares Jump 300% After Rare Disease Drug

3 weeks from now

Oct 7, 2024 · Scholar Rock's SRRK experimental drug achieved its main target in a late-stage trial for spinal muscular atrophy, the biotech company said on Monday, sending its shares soaring …

tradingview.com

30%
OFF

Scholar Rock Scores With ‘surprise’ Success In SMA Drug Study

3 weeks from now

Oct 7, 2024 · Additionally, 30% of those on Scholar Rock’s drug had at least a three-point improvement on a ratings scale widely used to evaluate SMA therapies. By comparison, …

yahoo.com

FAQs about Scholar Rock shares jump 300% after rare disease drug scores trial … Coupon?

Did scholar rock achieve its main target in a late-stage trial?

Scholar Rock's experimental drug achieved its main target in a late-stage trial for spinal muscular atrophy, the biotech company said on Monday, sending its shares soaring more than 300% in early trading. ...

How many patients did scholar rock take?

Scholar Rock enrolled 156 patients in the trial and used two doses. The company has won fast-track, orphan-drug and rare-pediatric-disease designations from the U.S. FDA, as well as priority-medicines and orphan medicinal product designations from the European Medicines Agency. ...

Could a new drug improve motor function in spinal muscular atrophy Patients?

The biotech company Scholar Rock reported Monday that its experimental medicine improved motor function in patients with a muscle-wasting disease called spinal muscular atrophy, paving the way for the likely approval of the drug. ...

How much did Scholar Rock Raise in a stock offering?

On the heels of Phase 3 data showing muscle improvement in the rare neuromuscular disease spinal muscular atrophy, Scholar Rock raised $300 million in a stock offering. U.S. and European regulatory submissions for the drug are now planned for early 2025. ...

Will scholar rock get regulatory approval after positive SMA results?

Scholar Rock is looking to file for regulatory approval in the US and EU after the positive data. Image credit: Shutterstock / eamesBot Scholar Rock’s stock has soared off the back of positive Phase III results from its spinal muscular atrophy (SMA) candidate. ...

Is scholar rock a good SMA drug?

Additionally, 30% of those on Scholar Rock’s drug had at least a three-point improvement on a ratings scale widely used to evaluate SMA therapies. By comparison, 12.5% of placebo recipients hit that mark. ...